Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL

French Innovative Leukemia Organisation

Status: Completed

Conditions: B Cell Chronic Lymphocytic Leukemia

Study type: Observational

Funder types: Other

Identifiers

NCT03502876

RESISTANCE A L'IBRUTINIB

Details and patient eligibility

About

Assessment of the mutational profile of the residual clone and the distribution of lymphocyte subpopulations at 3 years of treatment with ibrutinib

This project has an epidemiological part: to establish the percentage of patients, in a real-life situation, still undergoing treatment 3 years after its initiation, as well as a biological part: to determine the evolution of the clone and the prevalence of BTK mutations and PLCg2 in the absence of clinical or biological criteria for scalability.

Full description

Observationnal and biological study

Enrollment: 198 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients included in the ATU (epidemiology)
• under treatment at 3 years of ibrutinib
• more than 18 years old

Exclusion criteria

• no ibrutinib treatment